CVS adds Zepbound back to formulary, expands GLP-1 coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options
June 10, 2026 9:00 AM EDTExpanded GLP-1 options for members create a path to sustainable coverage of these important medications
WOONSOCKET, RI / ACCESS Newswire / June 10, 2026 / Originally published on CVS Health Company Newsroom
CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members- including the reintroduction of Zepbound® (tirzepatide) as a covered medication. These changes build on Caremark's industry leading efforts as a pharmacy benefits manager to explore all potential avenues... More
